Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.58 |
| ▸ | LMNA | P02545 | 2/20 | 0.57 |
| ▸ | USP2 | O75604 | 1/20 | 0.57 |
| ▸ | CPT1A | P50416 | 1/20 | 0.56 |
| ▸ | CPT1B | Q92523 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.55 |
| ▸ | MEN1 | O00255 | 3/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.55 |
| ▸ | FABP4 | P15090 | 1/20 | 0.55 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.54 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3556776 | 0.93 | LMNA (0.64) | L3MBTL1SMN1; SMN2LMNAUSP2ALDH1A1 | |
| SCHEMBL3559723 | 0.91 | L3MBTL1 (0.73) | L3MBTL1SMN1; SMN2LMNAALDH1A1MEN1 | |
| SCHEMBL3554579 | 0.90 | L3MBTL1 (0.67) | L3MBTL1SMN1; SMN2LMNAUSP2ALDH1A1 | |
| SCHEMBL3556994 | 0.85 | MEN1 (0.61) | L3MBTL1SMN1; SMN2LMNAUSP2ALDH1A1 | |
| SCHEMBL3561566 | 0.85 | CYP19A1 (0.61) | SMN1; SMN2LMNAALDH1A1MEN1KMT2A | |
| SCHEMBL3560653 | 0.84 | AKR1C3 (0.59) | SMN1; SMN2LMNAALDH1A1MEN1KMT2A | |
| SCHEMBL3567099 | 0.83 | CA12 (0.59) | SMN1; SMN2LMNAALDH1A1MEN1KMT2A | |
| SCHEMBL3556006 | 0.83 | MEN1 (0.64) | L3MBTL1SMN1; SMN2ALDH1A1MEN1KMT2A | |
| SCHEMBL3560262 | 0.80 | MEN1 (0.63) | L3MBTL1SMN1; SMN2ALDH1A1MEN1KMT2A | |
| SCHEMBL28816760 | 0.80 | ALPL (0.59) | L3MBTL1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7816397-B2 | Phenylcarboxylic acid derivatives and use thereof for the treatment of diabetes | MERCK PATENT GMBH (DE) | 2010-10-19 | — | — | US | claimed |
| US-20080045483-A1 | Phenylcarboxylic Acid Derivatives and Use Thereof for the Treatment of Diabetes | MERCK PATENT GMBH (DE) | 2008-02-21 | — | — | US | claimed |
| US-7816397-B2 | Phenylcarboxylic acid derivatives and use thereof for the treatment of diabetes | MERCK PATENT GMBH (DE) | 2010-10-19 | — | — | US | disclosed |
| US-20080045483-A1 | Phenylcarboxylic Acid Derivatives and Use Thereof for the Treatment of Diabetes | MERCK PATENT GMBH (DE) | 2008-02-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080045483-A1 | Phenylcarboxylic Acid Derivatives and Use Thereof for the Treatment of Diabetes | SLC5A1, ALDH7A1, ASS1 | L3MBTL1 2080/4885SMN1; SMN2 4522/4885LMNA 2120/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.